Originally published online as doi:10.1189/jlb.1102535 on May 22, 2003
Published online before print May 22, 2003
(Journal of Leukocyte Biology. 2003;74:161-166.)
© 2003
by Society for Leukocyte Biology
Control of myeloid activity during retinal inflammation
Andrew D. Dick*,
Debra Carter*,
Morag Robertson
,
Cathryn Broderick
,
Edward Hughes*,
John V. Forrester
and
Janet Liversidge
* Division of Ophthalmology, University of Bristol, United Kingdom;
Department of Ophthalmology, University of Aberdeen, United Kingdom; and
Institute of Ophthalmology, University College London, United Kingdom
Correspondence: Professor Andrew D. Dick, Division of Ophthalmology, University of Bristol, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK. E-mail: a.dick{at}Bristol.ac.uk

ABSTRACT
Combating myeloid cell-mediated destruction of the retina during
inflammation or neurodegeneration is dependent on the integrity
of homeostatic mechanisms within the tissue that may suppress
T cell activation and their subsequent cytokine responses, modulate
infiltrating macrophage activation, and facilitate healthy tissue
repair. Success is dependent on response of the resident myeloid-cell
populations [microglia (MG)] to activation signals, commonly
cytokines, and the control of infiltrating macrophage activation
during inflammation, both of which appear highly programmed
in normal and inflamed retina. The evidence that tissue CD200
constitutively provides down-regulatory signals to myeloid-derived
cells via cognate CD200-CD200 receptor (R) interaction supports
inherent tissue control of myeloid cell activation. In the retina,
there is extensive neuronal and endothelial expression of CD200.
Retinal MG in CD200 knockout mice display normal morphology
but unlike the wild-type mice, are present in increased numbers
and express nitric oxide synthase 2, a macrophage activation
marker, inferring that loss of CD200 or absent CD200R ligation
results in "classical" activation of myeloid cells. Thus, when
mice lack CD200, they show increased susceptibility to and accelerated
onset of tissue-specific autoimmunity.
Key Words: macrophages microglia CD200 sialoadhesin

INTRODUCTION
Intraocular inflammation is relatively uncommon yet remains
a leading cause of blindness within the working-age population
in developed countries [
1
,
2
]. The eye and in particular the
retina are regarded as immune-privileged sites providing the
environment for cellular and molecular mechanisms that suppress
inflammatory responses, while maintaining tissue homeostasis
and ultimately securing their vital function. An archetypal
example is that of anterior chamber-associated immune deviation,
where antigen delivered into the anterior segment of the eye
results in systemic down-regulation of systemic immunity, particularly
delayed-type hypersensitivity (DTH), to that antigen on subsequent
systemic exposure [
3
]. Mechanisms of suppression are numerous
and are in part reliant on an intact oculo-splenic axis and
ocular FasL expression [
4
5
6
7
]. Increasingly, it is appreciated
that the retina, like the anterior chamber of the eye, has active,
immune regulatory networks [
8
,
9
], which in combination with
the blood retinal barrier, protects against danger signals.
Despite the recognized immune privilege, within the eye, there
are dendritic cells (DCs) [
10
], but they are notably absent
from normal retina. However, early in retinal inflammation,
DCs have been described that infiltrate the perivascular space
within the glial limitans [
11
], similar to the recent findings
in the central nervous system (CNS) [
12
], so that a concept
that the initiation of CNS and retinal inflammation is in part
facilitated by recruitment of peripheral DC can be drawn. Whether
CNS or retina has resident cells that can confer antigen-presenting
cell (APC) ability remains controversial. There are two distinct
populations of myeloid-derived cells in the retina: perivascular
cells (PVCs) and microglia (MG) [
13
,
14
], where their role
as APC, immune effectors, or immunomodulators remains unconfirmed.
Unlike the CNS [
15
], in the retina, the majority of the myeloid
cell population is MG (
Fig. 1
) [
16
]. One inference is that
the resident MG, like their CNS counterparts, are pivotal to
restricting and regulating immune responses [
17
]. Given that
when intraocular inflammation affecting the retina occurs clinically,
it is frequently chronic and results in marked tissue destruction,
and questions arise as to how regulatory networks are overcome
and why there is a relative inability to restore tissue homeostasis.
The retina, like the brain, constitutes an environment that
interacts with the immune system and can regulate local immune
responses. Previously, it has been suggested that CNS pathologies
result in part as a result of failure of normal CNS mechanisms
[
17
]. These for example include a balance that exists between
astrocytes and MG, which serves on the one hand to suppress
MG-mediated T helper cell type 1 (Th1) responses and conversely,
to regulate tissue damage via astrocyte-mediated (nerve growth
factor) suppression of demyelination and possible concomitant
suppression of Th2 responses. Similarities of cell-cell interaction
to maintain homeostasis exist within retina. Recently, photoreceptor
survival during retinal degeneration has been linked with the
ability for MG activation to stimulate neurones (in the retina,
Muller cells), to secrete growth factors (such as basic fibroblast
growth factor), and to maintain photoreceptor survival [
18
,
19
]. There appear in the CNS and the retina tight cellular
interactions as well environmental conditions that govern the
continued viability and function of neuronal tissue. With respect
to leukocytes that are resident with such tissue, although many
soluble factors such as macrophage-colony stimulating factor
(M-CSF), granulocyte M-CSF, and various cytokines [
20
] play
a major role in the regulation and modification of myeloid cell
function, to date, relatively few surface-receptor factors have
been identified for this role. Leukocyte function, including
macrophages, may be regulated by the integration of activation
and inhibitory signals received through cell-surface receptors
[
21
]. In common with most of the inhibitory receptors is the
conservation of immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) in the cytoplasmic domains, although inhibitory molecules
such as cytotoxic T-lymphocyte antigen-4 lack this motif. Targeted
disruption of such molecules leads to an increase in autoimmune
disorders, which are frequently fatal [
22
]. A paradigm has
emerged where the strength of the opposing, activating, and
inhibitory signals determine the initiation, amplification,
and termination of immune responses [
23
]. This review will
present an overview of the environmental conditions and cognate
cellular interactions that provide regulation of local immune
responses and maintenance of tissue/neuronal integrity, first
alluding to the role of the retinal microenvironment and cognate
interactions that control resident MG and the influence and
control of infiltrating macrophages by the retina during inflammation.

THE RETINAL ENVIRONMENT AND MG
MG are derived from myeloid cell lineage. Macrophages isolated
from different tissues and anatomical sites are heterogeneous,
and it has long been recognized that resident macrophages are
adapted to the local microenvironment [
24
,
25
]. Observations
from development studies [
26
], depletion studies [
27
], and
differentiation show that the tissue regulates macrophage function
[
28
]. Injury leads to a rapid increase in the number of macrophages
in an inflamed tissue, and these cells adapt to the local microenvironment
by development of a coordinated set of properties that enable
them to perform a particular function. Programming is arguably
determined by the first cytokine to which macrophages are exposed,
from which an essential component of the program is the development
of unresponsiveness to other activating cytokines [
20
]. Glomerular
macrophages for instance are uncommitted and can be prevented
from responding to interferon-

(IFN-

) when pretreated with transforming
growth factor-ß (TGF-ß) in vivo [
29
30
31
].
The concept of macrophage activation (see review, ref. [
32
])
includes the ability of macrophages to adapt to signals that
drive cells into "classical" and "alternative" pathways by IFN-
or interleukin (IL)-4/IL-13-generating immunity/DTH or repair
responses, respectively. Additionally, macrophages may respond
to innate signals via Toll-like receptor or deactivating signals
via TGF-ß, CD47, CD200 receptor (R), and others. In
keeping with many of the recent concepts and paradigms of macrophage
activation, in the retina, MG adapt to control neuronal growth
and are active phagocytes, clearing dying photoreceptor cells
[
33
], whereupon responses to photoreceptor degeneration and
retinal injury incur MG migration and accumulation [
34
]. For
example, resting MG express low levels of CD45 and costimulatory
molecules [
15
,
35
] and possess minimal migration and phagocytic
activity in situ, all of which may contribute to immune regulation
[
36
] induced by TGF-ß {in turn secreted by the retinal
pigment epithelium (RPE) [
37
]} programming of myeloid activity.
During circumstances of injury or immune-mediated stress, retinal
or CNS MG are "activated", associated with up-regulation of
CD45, coaccessory molecules, MHC class II expression, and cytokine
secretion; migration; and the ability to phagocytose apoptotic
cells. To dissect myeloid cell behavior further, we developed
a retinal explant model, from where MG readily migrate and display
mannan receptor-mediated phagocytosis [
38
]. There have been
many reports on the central role of IL-10 in the maintenance
of ocular-immune regulation [
39
,
40
]. In context of normal
retina, MG in retinal explants, stimulated with a classical
activation cocktail of IFN-

/lipopolysaccharide (LPS), do not
respond like uncommitted macrophages but secrete IL-10, which
in turn down-regulates B7 complex and CD40 expression and migration
[
38
,
41
] and suppresses production of IL-12 or expression
of nitric oxide synthase (NOS)2 or generation of NO. However,
given the phenotypic propensity to present antigen, much work
in the CNS to date has focused on the MG ability to do so, and
success depends on whether functional assays have studied neonatal
MG or MG cultures [
17
]. Following isolation of MG and perivascular
macrophages, direct ex vivo analysis shows that it is the latter
that are able to present antigen and not MG [
42
]. Furthermore,
although MG interact with T cells [
43
] and support activated
T cell effector responses, they do not support IL-2 production
or proliferation, and T cell apoptosis results [
42
]. MG, therefore,
unlike perivascular macrophage counterparts, provide novel,
regulatory measures to down-regulate immune-mediated responses
within the retina and CNS and limit tissue damage. Indeed, one
implication is that the ability to phagocytose apoptotic cells
may in turn down-regulate MG ability to present antigen, akin
to macrophage behavior in general [
30
,
31
], thus limiting
prolonged tissue-damaging effects of immune responses during
neurodegeneration.
Control of microglial activation in situ in normal retina
Recent investigations of CD200 (OX2), a member of the immunoglobulin (Ig) superfamily, and CD200R have demonstrated that macrophages and granulocytes are restrained from tissue-damaging activation through CD200R signaling [44
45
46
]. The studies demonstrated that CD200 and CD200R are glycoproteins and that CD200R is confined to myeloid cells, which in turn can be phosphorylated on tyrosine residues. Moreover, earlier experiments showed that a blockade of CD200:CD200R resulted in exacerbation of experimental allergic encephalomyelitis (EAE), which together with data from knockout (KO) mice (see below), strongly support a control of myeloid activity by CD200 [46
]. CD200KO mice demonstrate an increase in myeloid cell numbers, and aggregates in peripheral lymphoid tissue and resident myeloid cell populations within the CNS phenotypically and morphologically appeared activated [45
] and elicited an exaggerated MG response upon facial nerve transection. In retina, there is widespread expression of CD200 on glial fibrillary acidic protein neurones and endothelium, and CD200R (in the rat at least) is expressed on MG and up-regulated on activated MG during retinal inflammation [47
]. Regulation of macrophage function is supported by the following observations in CD200KO mice: significant increase in numbers of myeloid-derived cells within lymphoid organs [48
], activation of MG to express NOS2 [49
], accelerated onset of experimental autoimmune uveoretinitis (EAU) [49
] and experimental autoimmune EAE, and conversion of C57BL/6 mice from resistant to susceptible to collagen-induced arthritis [45
]. Using a retinal explant model [38
, 41
], we have further shown with preliminary data that MG migration is facilitated by CD200R ligation via CD200:Fc, while inhibiting the effect of IFN-
/LPS activity on MG (Fig. 2
) and preventing classical activation of resident MG. This implies, in addition to control of macrophage activation to express for example NOS2, CD200R also signals MG to migrate. Consequently, the role of CD200 expression on endothelium requires further elucidation as to its effects on circulating myeloid cells. The constitutive down-regulation of CNS and retinal macrophages has important implications on how potential deregulation of the CD200:CD200R axis affects not only the course and the severity of autoimmune inflammation but also generation of and tissue response to neurodegenerative conditions.

MACROPHAGE ACTIVITY DURING RETINAL DEGENERATION
The main studies have concentrated on the control of macrophage
activity during inflammation and not neurodegeneration. The
rds mouse provides a useful model for human outer retinal dystrophies.
The mouse is homozygous for a null mutation in the Prph2 gene
that encodes the structural protein peripherin/rds, essential
for the formation and maintenance of normal photoreceptor outer
segments, and thus, without which, photoreceptor apoptosis results
[
50
]. During neurodegeneration in
rds mice, MG become activated,
proliferate, and express sialoadhesin but not NOS2 and do not
generate nitrotyrosine (E. Hughes et al., submitted manuscript).
The control of MG activity during neurodenegeration and therefore
subsequent MG behavior is largely ill-defined. Recent experiments
in the
rds mouse showed that the greatest photoreceptor death
precedes the height of MG activity by at least 5 days, and although
MG proliferated, there was no evidence of NO-mediated oxidative
damage. Whether MG are deregulated and exacerbate photoreceptor
degeneration or in fact respond to limit tissue damage as a
result of their microenvironmental conditioning requires further
investigation, particularly in light of the observation that
there is marked sialoadhesin expression during the course of
degeneration. Sialoadhesin is one of a group of macrophage-restricted
cell-surface sialic acid receptor proteins named siglecs [
51
,
52
], which has a high degree of conservation between rodents
and humans. Their precise role in macrophage function is yet
to be fully clarified, but they are thought to be involved in
cell-cell and cell-extracellular matrix (ECM) interactions,
and human siglecs have structural similarities to ITIMs, which
have a regulatory influence over macrophage activity [
53
].
Although sialoadhesin is not thought to be a phagocytic receptor,
its expression may facilitate other phagocytic receptors and
increase cell-cell and cell-ECM adhesion. Whether this is also
involved in bridging innate and acquired immune responses by
binding to CD43-positive T cells [
54
] is an avenue for further
investigation during neurodegeneration.

CONTROL OF MACROPHAGE ACTIVITY DURING INFLAMMATION
Macrophages entering an inflamed site are placed in an environment
where they are exposed to many different signals. Up until now,
this review has focused on evidence that resident macrophages,
such as MG, in retina and CNS are maintained so as not to "classically"
activate unless overrun by environmental conditions such as
injury, degeneration, or overwhelming inflammation. Additionally,
there is evidence that trafficking of macrophages occurs in
normal CNS tissue, but these cells fail to respond classically
to acute inflammatory stimuli [
55
]. Whether during inflammation,
the retina maintains a capacity to down-regulate classical activation
of infiltrating macrophages or "alternatively" activate macrophages
has not previously been defined. Such observations would demonstrate
an inherent capacity of the tissue environment to contribute
toward neuronal repair and open avenues for developing therapeutic
strategies during inflammation. Therefore, using the model EAU,
a CD4
+ T cell-mediated antigen-specific destruction of the retina
[
56
57
58
], we can further dissect the control of myeloid cell
activity during inflammation. For full disease expression of
EAU, a nonspecific macrophage infiltrate is required [
59
,
60
].
In this set of experiments, resident MG behave as though conditioned
with TGF-ß and under the influence of CD200R signaling
do not express NOS2 but express ß-glucuronidase [
49
,
61
]. During the evolution, peak, and resolution of EAU, infiltrating
macrophages show differential programming. Classical macrophage
activation following stimulation with IFN-

and tumor necrosis
factor (TNF) refers to the ability of a macrophage to express
NOS2 and generate nitrite, peroxynitrites, and superoxides,
which in turn induces lipid peroxidation of cell membranes and
cell death. This is observed during the overwhelming inflammatory
response of peak-phase EAU [
61
]. Like resident MG, which behave
as though TGF-ß primed and are resistant to further
cytokine stimulation, the abundant number of macrophages isolated
during EAU recovery behaves similarly and does not produce nitrite
[
41
,
61
]. In peak EAU, infiltrating myeloid cells under the
influence of the pronounced cytokine release from the Th1 T
cell infiltrate express NOS2 and nitrotyrosine and constitutively
release NO. The destructive role of classically activated macrophages
has been further demonstrated in experiments where inhibition
of NOS2 suppresses expression of and tissue destruction seen
in EAU by preventing peroxynitrite formation by macrophages,
thus protecting photoreceptor cells from apoptosis [
62
,
63
].
A similar picture is seen when animals evolving EAU are treated
with soluble p55 TNF receptor-IgG fusion protein (sTNFr-Ig)
[
35
]. All these sets of experiments have furthered our understanding
of macrophage conditioning during EAU, the inherent ability
of the retina to control macrophage activation, and in the latter
experiments, the mechanisms by which anti-TNF therapies are
active during suppression of target organ damage. sTNFr-Ig suppresses
clinical EAU and tissue damage without significantly altering
the retinal T cell or macrophage infiltrate [
35
,
64
]. Treatment
does suppress T cell-derived IFN-

production [
64
] and macrophage-derived
NO production during the height of disease. It is possible that
sTNFr-Ig binds and inhibits soluble TNF (solTNF) and membrane
TNF (memTNF) on T cells, thus preventing T cell activation and
IFN-

production and subsequent IFN-

/TNF-mediated activation
of infiltrating macrophages during EAU. Generally, however,
solTNF is regarded as the ligand for p55 or TNFr1 [
65
]. TNFr1
contains death domains mediating apoptosis upon engagement [
66
]
but also under other circumstances, may mediate cell survival
[
67
]. Recent evidence strongly infers that memTNF supports
the generation of lymphoid structures, and solTNF is required
for the generation of full phenotype of inflammatory lesions,
as shown in experimental models of autoimmunity within the CNS
[
68
]. That sTNFr-Ig treatment delayed but did not impair cell
movement into the retina yet did suppress the full phenotype
of tissue damage implies in the main that the principal action
is against solTNF. If that is the case, then the main action
opposes T cell-derived TNF and IFN-

production, which in turn
reduces the ability to activate macrophages when infiltrating
the retina. Studies emphasize the distinct roles for macrophages
at different stages during the evolution of EAU and the importance
of homeostatic control of resident macrophage populations as
well as infiltrating macrophage programming in determining which
role they adopt. Such regulation permits the down-regulation
of macrophage activity and allows, with subsequent redress of
the microenvironment during disease course, a new influx of
macrophages to be alternatively programmed and provide different
functions.

CONCLUDING REMARKS
The retina, similar to the CNS, is empowered with numerous mechanisms
to respond to danger effectively, control inflammation, and
resume normal function without a debilitating healing response
(
Fig. 3
). This requires a fine balance between the control
of resident myeloid cell population, principally MG, via cognate
interaction of CD200 ligand on endothelium and neurons and its
receptor expressed on macrophages. The result is a continual
down-regulation of classical macrophage activation to generate
NO in response to IFN-

and TNF-

, for instance, and a reduction
in the capacity to present antigen but to maintain phagocytic
activity to presumably allow clearance of apoptotic bodies (photoreceptors)
and debris. In support of endothelial CD200 expression facilitating
trafficking of cells, we have noted that MG maintain migratory
capacity with CD200:Fc. Cytokines also play a major role, and
it is the loss of the predominant and constant TGF-ß
conditioning of myeloid cells in the steady-state, overridden
by the hierarchical Th1 cytokine response that conditions infiltrating
macrophages during inflammation, which delivers the full expression
of, in particular, the autoimmune response. Nevertheless, CD200
interaction and TGF-ß conditioning rapidly reprogram
newly infiltrated cells during resolution, orchestrating tissue
repair and the return to the steady-state.

ACKNOWLEDGEMENTS
The work was supported by Iris fund for the Prevention of Blindness,
U.K., Guide Dogs for the Blind Association, U.K., National Eye
Research Centre, U.K., and the Wellcome Trust.
Received November 8, 2002;
revised January 7, 2003;
accepted January 10, 2003.

REFERENCES
1 - Guex-Crosier, Y. (1999) The pathogenesis and clinical presentation of macular edema in inflammatory diseases Doc. Ophthalmol. 97,297-309[CrossRef][Medline]
2 - Rothova, A., Suttorp-van Schulten, M. S., Frits Treffers, W., Kijlstra, A. (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease Br. J. Ophthalmol. 80,332-336[Abstract/Free Full Text]
3 - Streilein, J. W., Niederkorn, J. Y. (1981) Induction of anterior chamber-associated immune deviation requires an intact, functional spleen J. Exp. Med. 153,1058-1067[Abstract/Free Full Text]
4 - Streilein, J. W. (1997) Molecular basis of ACAID Ocul. Immunol. Inflamm. 5,217-218[Medline]
5 - Ferguson, T. A. (1997) The molecular basis of anterior associated immune deviation (ACAID) Ocul. Immunol. Inflamm. 5,213-215[Medline]
6 - Streilein, J. W., Masli, S., Takeuchi, M., Kezuka, T. (2002) The eyes view of antigen presentation Hum. Immunol. 63,435-443[CrossRef][Medline]
7 - Griffith, T. S., Ferguson, T. A. (1997) The role of FasL-induced apoptosis in immune privilege Immunol. Today 18,240-244[CrossRef][Medline]
8 - Wenkel, H., Chen, P. W., Ksander, B. R., Streilein, J. W. (1999) Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space Invest. Ophthalmol. Vis. Sci. 40,3202-3208[Abstract/Free Full Text]
9 - Welge-Lussen, U., Wilsch, C., Neuhardt, T., Wayne Streilein, J., Lutjen-Drecoll, E. (1999) Loss of anterior chamber-associated immune deviation (ACAID) in aged retinal degeneration (rd) mice Invest. Ophthalmol. Vis. Sci. 40,3209-3214[Abstract/Free Full Text]
10 - Forrester, J. V., McMenamin, P. G., Holthouse, I., Lumsden, L., Liversidge, J. (1994) Localization and characterization of major histocompatibility complex class II-positive cells in the posterior segment of the eye: implications for induction of autoimmune uveoretinitis Invest. Ophthalmol. Vis. Sci. 35,64-77[Abstract/Free Full Text]
11 - Jiang, H. R., Lumsden, L., Forrester, J. V. (1999) Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice Invest. Ophthalmol. Vis. Sci. 40,3177-3185[Abstract/Free Full Text]
12 - Serafini, B., Columba-Cabezas, S., Di Rosa, F., Aloisi, F. (2000) Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis Am. J. Pathol. 157,1991-2002[Abstract/Free Full Text]
13 - Provis, J. M., Penfold, P. L., Edwards, A. J., van Driel, D. (1995) Human retinal microglia: expression of immune markers and relationship to the glia limitans Glia 14,243-256[CrossRef][Medline]
14 - Provis, J. M., Diaz, C. M., Penfold, P. L. (1996) Microglia in human retina: a heterogeneous population with distinct ontogenies Perspect. Dev. Neurobiol. 3,213-222[Medline]
15 - Ford, A. L., Goodsall, A. L., Hickey, W. F., Sedgwick, J. D. (1995) Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared J. Immunol. 154,4309-4321[Abstract]
16 - Dick, A. D., Ford, A. L., Forrester, J. V., Sedgwick, J. D. (1995) Flow cytometric identification of a minority population of MHC class II-positive cells in the normal rat retina distinct from CD45lowCD11b/c+CD4low parenchymal microglia Br. J. Ophthalmol. 79,834-840[Abstract/Free Full Text]
17 - Xiao, B. G., Link, H. (1999) Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? Immunol. Today 20,477-479[CrossRef][Medline]
18 - Harada, T., Harada, C., Nakayama, N., Okuyama, S., Yoshida, K., Kohsaka, S., Matsuda, H., Wada, K. (2000) Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration Neuron 26,533-541[CrossRef][Medline]
19 - Harada, T., Harada, C., Kohsaka, S., Wada, E., Yoshida, K., Ohno, S., Mamada, H., Tanaka, K., Parada, L. F., Wada, K. (2002) Microglia-Muller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration J. Neurosci. 22,9228-9236[Abstract/Free Full Text]
20 - Erwig, L., Kluth, D. C., Walsh, G. M., Rees, A. J. (1998) Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines J. Immunol. 161,1983-1988[Abstract/Free Full Text]
21 - Lu, Q., Lemke, G. (2001) Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family Science 293,306-311[Abstract/Free Full Text]
22 - Ravetch, J. V., Lanier, L. L. (2000) Immune inhibitory receptors Science 290,84-89[Abstract/Free Full Text]
23 - Lanier, L. L. (2001) Face off-the interplay between activating and inhibitory immune receptors Curr. Opin. Immunol. 13,326-331[CrossRef][Medline]
24 - Forrester, J. V., McMenamin, P. G. (1999) Immunopathogenic mechanisms in intraocular inflammation Chem. Immunol. 73,159-185[Medline]
25 - Laszlo, D. J., Henson, P. M., Remigio, L. K., Weinstein, L., Sable, C., Noble, P. W., Riches, D. W. (1993) Development of functional diversity in mouse macrophages. Mutual exclusion of two phenotypic states Am. J. Pathol. 143,587-597[Abstract]
26 - Takahashi, K., Yamamura, F., Naito, M. (1989) Differentiation, maturation, and proliferation of macrophages in the mouse yolk sac: a light-microscopic, enzyme-cytochemical, immunohistochemical, and ultrastructural study J. Leukoc. Biol. 45,87-96[Abstract]
27 - Yamada, M., Naito, M., Takahashi, K. (1990) Kupffer cell proliferation and glucan-induced granuloma formation in mice depleted of blood monocytes by strontium-89 J. Leukoc. Biol. 47,195-205[Abstract]
28 - Naito, M., Umeda, S., Yamamoto, T., Moriyama, H., Umezu, H., Hasegawa, G., Usuda, H., Shultz, L. D., Takahashi, K. (1996) Development, differentiation, and phenotypic heterogeneity of murine tissue macrophages J. Leukoc. Biol. 59,133-138[Abstract]
29 - Erwig, L. P., Stewart, K., Rees, A. J. (2000) Macrophages from inflamed but not normal glomeruli are unresponsive to anti-inflammatory cytokines Am. J. Pathol. 156,295-301[Abstract/Free Full Text]
30 - Barker, R. N., Erwig, L., Pearce, W. P., Devine, A., Rees, A. J. (1999) Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages Pathobiology 67,302-305[CrossRef][Medline]
31 - Barker, R. N., Erwig, L. P., Hill, K. S., Devine, A., Pearce, W. P., Rees, A. J. (2002) Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells Clin. Exp. Immunol. 127,220-225[CrossRef][Medline]
32 - Gordon, S. (2003) Alternative activation of macrophages Nat. Rev. Immunol. 3,23-35[CrossRef][Medline]
33 - Egensperger, R., Maslim, J., Bisti, S., Hollander, H., Stone, J. (1996) Fate of DNA from retinal cells dying during development: uptake by microglia and macroglia (Muller cells) Brain Res. Dev. Brain Res. 97,1-8[Medline]
34 - Roque, R. S., Imperial, C. J., Caldwell, R. B. (1996) Microglial cells invade the outer retina as photoreceptors degenerate in Royal College of Surgeons rats Invest. Ophthalmol. Vis. Sci. 37,196-203[Abstract/Free Full Text]
35 - Dick, A. D., McMenamin, P. G., Korner, H., Scallon, B. J., Ghrayeb, J., Forrester, J. V., Sedgwick, J. D. (1996) Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina Eur. J. Immunol. 26,1018-1025[Medline]
36 - Dick, A. D. (1999) Immune regulation of uveoretinal inflammation Dev. Ophthalmol. 30,187-202[CrossRef][Medline]
37 - Crane, I. J., Kuppner, M. C., McKillop-Smith, S., Wallace, C. A., Forrester, J. V. (1999) Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human retinal pigment epithelial cells Clin. Exp. Immunol. 115,288-293[CrossRef][Medline]
38 - Broderick, C., Duncan, L., Taylor, N., Dick, A. D. (2000) IFN-gamma and LPS mediated IL-10-dependent suppression of retinal microglial activation Invest. Ophthalmol. Vis. Sci. 41,2613-2622[Abstract/Free Full Text]
39 - DOrazio, T. J., Niederkorn, J. Y. (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege J. Immunol. 160,2089-2098[Abstract/Free Full Text]
40 - Sonoda, K. H., Faunce, D. E., Taniguchi, M., Exley, M., Balk, S., Stein-Streilein, J. (2001) NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance J. Immunol. 166,42-50[Abstract/Free Full Text]
41 - Carter, D. A., Dick, A. D. (2003) Interferon-
/lipopolysaccharide and not TGFß inhibits retinal microglial migration from retinal explant Br. J. Ophthalmol. 87,481-487[Abstract/Free Full Text]
42 - Ford, A. L., Foulcher, E., Lemckert, F. A., Sedgwick, J. D. (1996) Microglia induce CD4 T lymphocyte final effector function and death J. Exp. Med. 184,1737-1745[Abstract/Free Full Text]
43 - Sedgwick, J. D., Ford, A. L., Foulcher, E., Airriess, R. (1998) Central nervous system microglial cell activation and proliferation follows direct interaction with tissue-infiltrating T cell blasts J. Immunol. 160,5320-5330[Abstract/Free Full Text]
44 - Wright, G. J., Jones, M., Puklavec, M. J., Brown, M. H., Barclay, A. N. (2001) The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans Immunology 102,173-179[CrossRef][Medline]
45 - Hoek, R. M., Ruuls, S. R., Murphy, C. A., Wright, G. J., Goddard, R., Zurawski, S. M., Blom, B., Homola, M. E., Streit, W. J., Brown, M. H., Barclay, A. N. (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200) Science 290,1768-1771[Abstract/Free Full Text]
46 - Wright, G. J., Puklavec, M. J., Willis, A. C., Hoek, R. M., Sedgwick, J. D., Brown, M. H., Barclay, A. N. (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function Immunity 13,233-242[CrossRef][Medline]
47 - Dick, A. D., Broderick, C., Forrester, J. V., Wright, G. J. (2001) Distribution of OX2 antigen and OX2 receptor within retina Invest. Ophthalmol. Vis. Sci. 42,170-176[Abstract/Free Full Text]
48 - Wright, G. J., Puklavec, M. J., Willis, A. C., Hoek, R. M., Sedgwick, J. D., Brown, M. H., Barclay, A. N. (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognises a novel receptor on macrophages implicated in their control of function Immunity 13,233-238
49 - Broderick, C., Hoek, R. M., Forrester, J. V., Liversidge, J., Sedgwick, J. D., Dick, A. D. (2002) Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis Am. J. Pathol. 161,1669-1677[Abstract/Free Full Text]
50 - Connell, G., Bascom, R., Molday, L., Reid, D., McInnes, R. R., Molday, R. S. (1991) Photoreceptor peripherin is the normal product of the gene responsible for retinal degeneration in the rds mouse Proc. Natl. Acad. Sci. USA 88,723-726[Abstract/Free Full Text]
51 - Crocker, P. R., Varki, A. (2001) Siglecs in the immune system Immunology 103,137-145[CrossRef][Medline]
52 - Crocker, P. R., Varki, A. (2001) Siglecs, sialic acids and innate immunity Trends Immunol 22,337-342[CrossRef][Medline]
53 - Crocker, P. R., Clark, E. A., Filbin, M., Gordon, S., Jones, Y., Kehrl, J. H., Kelm, S., Le Douarin, N., Powell, L., Roder, J., Schnaar, R. L., Sgroi, D. C., Stamenkovic, K., Schauer, R., Schachner, M., van den Berg, T. K., van der Merwe, P. A., Watt, S. M., Varki, A. (1998) Siglecs: a family of sialic-acid binding lectins Glycobiology 8
54 - van den Berg, T. K., Nath, D., Ziltener, H. J., Vestweber, D., Fukuda, M., van Die, I., Crocker, P. R. (2001) Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1) J. Immunol. 166,3637-3640[Abstract/Free Full Text]
55 - Andersson, P. B., Perry, V. H., Gordon, S. (1992) The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues Neuroscience 48,169-186[CrossRef][Medline]
56 - Forrester, J. V., Liversidge, J., Dua, H. S., Dick, A., Harper, F., McMenamin, P. G. (1992) Experimental autoimmune uveoretinitis: a model system for immunointervention: a review Curr. Eye Res. 11,33-40
57 - Caspi, R. R., Roberge, F. G., Chan, C. C., Wiggert, B., Chader, G. J., Rozenszajn, L. A., Lando, Z., Nussenblatt, R. B. (1988) A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens J. Immunol. 140,1490-1495[Abstract]
58 - Caspi, R. R., Roberge, F. G., McAllister, C. G., el-Saied, M., Kuwabara, T., Gery, I., Hanna, E., Nussenblatt, R. B. (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat J. Immunol. 136,928-933[Abstract]
59 - Forrester, J. V., Huitinga, I., Lumsden, L., Dijkstra, C. D. (1998) Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats Curr. Eye Res. 17,426-437[Medline]
60 - Caspi, R. R., Chan, C. C., Fujino, F., Najafian, F., Grover, C. T., Hansen, C. T., Wilder, R. L. (1993) Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis J. Neuroimmunol. 47,177-183[CrossRef][Medline]
61 - Robertson, M. J., Erwig, L. P., Liversidge, J., Forrester, J. V., Rees, A. J., Dick, A. D. (2002) Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis Invest. Ophthalmol. Vis. Sci. 43,2250-2257[Abstract/Free Full Text]
62 - Liversidge, J., Dick, A., Gordon, S. (2002) Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis Am. J. Pathol. 160,905-916[Abstract/Free Full Text]
63 - Hoey, S., Brabowski, P. S., Ralston, S. H., Forrester, J. V., Liversidge, J. (1997) Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis J. Immunol. 159,5132-5137[Abstract]
64 - Dick, A. D., Duncan, L., Hale, G., Waldmann, H., Isaacs, J. (1998) Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis J. Autoimmun. 11,255-264[CrossRef][Medline]
65 - Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor Cell 83,793-802[CrossRef][Medline]
66 - Grell, M., Zimmermann, G., Gottfried, E., Chen, C. M., Grunwald, U., Huang, D. C., Wu Lee, Y. H., Durkop, H., Engelmann, H., Scheurich, P., Wajant, H., Strasser, A. (1999) Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF EMBO J 18,3034-3043[CrossRef][Medline]
67 - Cope, A. P., Liblau, R. S., Yang, X. D., Congia, M., Laudanna, C., Schreiber, R. D., Probert, L., Kollias, G., McDevitt, H. O. (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling J. Exp. Med. 185,1573-1584[Abstract/Free Full Text]
68 - Ruuls, S. R., Hoek, R. M., Ngo, V. N., McNeil, T., Lucian, L. A., Janatpour, M. J., Korner, H., Scheerens, H., Hessel, E. M., Cyster, J. G., McEvoy, L. M., Sedgwick, J. D. (2001) Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation Immunity 15,533-543[CrossRef][Medline]
69 - Barclay, A. N., Wright, G. J., Brooke, G., Brown, M. H. (2002) CD200 and membrane protein interactions in the control of myeloid cells Trends Immunol 23,285-290[CrossRef][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
D. A. Copland, C. J. Calder, B. J.E. Raveney, L. B. Nicholson, J. Phillips, H. Cherwinski, M. Jenmalm, J. D. Sedgwick, and A. D. Dick
Monoclonal Antibody-Mediated CD200 Receptor Signaling Suppresses Macrophage Activation and Tissue Damage in Experimental Autoimmune Uveoretinitis
Am. J. Pathol.,
August 1, 2007;
171(2):
580 - 598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Feuer
Tickling the CD200 Receptor: A Remedy for Those Irritating Macrophages
Am. J. Pathol.,
August 1, 2007;
171(2):
396 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Langmann
Microglia activation in retinal degeneration
J. Leukoc. Biol.,
June 1, 2007;
81(6):
1345 - 1351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Antonetti, A. J. Barber, S. K. Bronson, W. M. Freeman, T. W. Gardner, L. S. Jefferson, M. Kester, S. R. Kimball, J. K. Krady, K. F. LaNoue, et al.
Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease
Diabetes,
September 1, 2006;
55(9):
2401 - 2411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Guyver, D. A. Copland, C. J. Calder, A. Sette, J. Sidney, A. D. Dick, and L. B. Nicholson
Mapping Immune Responses to mRBP-3 1-16 Peptide with Altered Peptide Ligands
Invest. Ophthalmol. Vis. Sci.,
May 1, 2006;
47(5):
2027 - 2035.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V T Pham, L Wen, P McCluskey, M C Madigan, and P L Penfold
Human retinal microglia express candidate receptors for HIV-1 infection
Br J Ophthalmol,
June 1, 2005;
89(6):
753 - 757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Gregerson, T. N. Sam, and S. W. McPherson
The Antigen-Presenting Activity of Fresh, Adult Parenchymal Microglia and Perivascular Cells from Retina
J. Immunol.,
June 1, 2004;
172(11):
6587 - 6597.
[Abstract]
[Full Text]
[PDF]
|
 |
|